Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From White House To White Oak: US FDA Taps Stacy Cline Amin For Chief Counsel Post

Executive Summary

Agency’s new top lawyer brings deep knowledge of drug regulatory and legislative matters from her time on Capitol Hill and strong ties to the White House, where she has worked as special assistant and senior associate counsel to President Trump since early 2017.

You may also be interested in...



FDA Chief Counsel Stacy Cline Amin Guided Agency Through COVID-19 EUAs And Guidances

Amin leaves after two-year stint, but Trump administration chaos continues as HHS names a different replacement chief counsel than FDA did earlier in the day. James Lawrence is tapped to be FDA's top lawyer and will presumably help speed a number of regulatory changes at the agency.  

FDA’s Gottlieb Says His Departure Won’t Stop Forward Progress On Key Initiatives

Outgoing commissioner say he has 'extreme confidence' in soon-to-be-acting Commissioner Ned Sharpless and other agency leaders, and expects initiatives advanced during his tenure will be ‘encapsulated and enshrined in regulation and policy’ because they are built on a solid administrative record.

US Enforcement 2019: Compounding, Opioids Top Priorities But Beware Of REMS Violations, Too

Drug manufacturer reimbursement support services also are garnering a growing amount of enforcement attention, and misleading promotion - whether on- or off-label - remains on the radar of government investigators.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS123836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel